Suppr超能文献

链阳菌素和大环内酯类的作用机制。

Mechanism of action of streptogramins and macrolides.

作者信息

Vannuffel P, Cocito C

机构信息

Department of Genetics and Microbiology, Catholic University of Louvain, Brussels, Belgium.

出版信息

Drugs. 1996;51 Suppl 1:20-30. doi: 10.2165/00003495-199600511-00006.

Abstract

Protein synthesis is catalysed by ribosomes and cytoplasmic factors. Bacterial ribosomes (70S) are made up of 2 subunits (50S and 30S) containing ribosomal RNA (rRNA) and ribosomal proteins: the 30S binds messenger RNA and begins the ribosomal cycle (initiation), whereas 50S binds transfer RNA (tRNA) derivatives and controls elongation. The key reaction, peptide bond formation, is promoted by the catalytic centre of 50S (the peptidyl transferase centre), and the growing peptide chain (peptidyl-tRNA) attached at the donor P site undergoes peptide linkage with an aminoacyl-tRNA at the acceptor A site. This reaction is inhibited by several antibiotics, the best known being chloramphenicol, and the macrolide-lincosamide-streptogramin (MLS) group. These inhibitors have a reversible action, except for streptogramins that are composed of A and B components, which are bacteriostatic alone, but bactericidal when combined. The peptidyl transferase centre has been identified at the 50S surface, and the binding sites of inhibitors have been mapped within this domain: some of these sites overlap (e.g. those of macrolides, and type B streptogramins, which compete for binding to ribosomes). Chloramphenicol blocks the catalytic portion, and A streptogramins the substrate sites of the peptidyl transferase centre. Macrolides and type B streptogramins interfere with the formation of long polypeptides and cause a premature detachment of incomplete peptide chains. The synergism between types A and B streptogramins is due to induction by type A streptogramins of an increased ribosome affinity for type B streptogramins. Microbial resistance to antibiotics mainly involves inactivation of inhibitors and modification of targets (mutations of ribosomal proteins or rRNA genes). Alterations of rRNA bases can induce resistance to a single inhibitor or to a group of antibiotics (e.g. MLSB). The impact of resistance in chemotherapy is less important for streptogramins than for other inhibitors, because the synergistic effect of A and B streptogramins also applies to strains resistant to the MLSB group. It is proposed that mutations and modifications of rRNA bases induce conformational ribosomal changes that prevent antibiotics binding to the target. Conformational changes are also triggered by type A streptogramins: they are responsible for their synergism with type B streptogramins.

摘要

蛋白质合成由核糖体和细胞质因子催化。细菌核糖体(70S)由两个亚基(50S和30S)组成,包含核糖体RNA(rRNA)和核糖体蛋白:30S结合信使RNA并启动核糖体循环(起始),而50S结合转移RNA(tRNA)衍生物并控制延伸。关键反应,即肽键形成,由50S的催化中心(肽基转移酶中心)促进,连接在供体P位点的正在生长的肽链(肽基-tRNA)在受体A位点与氨酰-tRNA发生肽键连接。该反应受到几种抗生素的抑制,最著名的是氯霉素以及大环内酯-林可酰胺-链阳霉素(MLS)组。除了由A和B组分组成的链阳霉素外,这些抑制剂具有可逆作用,A和B组分单独使用时具有抑菌作用,但联合使用时具有杀菌作用。肽基转移酶中心已在50S表面被鉴定出来,抑制剂的结合位点已在该结构域内定位:其中一些位点重叠(例如大环内酯类和B型链阳霉素的位点,它们竞争与核糖体的结合)。氯霉素阻断催化部分,A类链阳霉素阻断肽基转移酶中心的底物位点。大环内酯类和B型链阳霉素干扰长多肽的形成并导致不完全肽链过早脱离。A类和B类链阳霉素之间的协同作用是由于A类链阳霉素诱导核糖体对B类链阳霉素的亲和力增加。微生物对抗生素的耐药性主要涉及抑制剂的失活和靶点的修饰(核糖体蛋白或rRNA基因的突变)。rRNA碱基的改变可诱导对单一抑制剂或一组抗生素(如MLSB)的耐药性。链阳霉素在化疗中耐药性的影响比其他抑制剂小,因为A类和B类链阳霉素的协同作用也适用于对MLSB组耐药的菌株。有人提出,rRNA碱基的突变和修饰会诱导核糖体构象变化,从而阻止抗生素与靶点结合。构象变化也由A类链阳霉素触发:它们负责其与B类链阳霉素的协同作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验